Compare · CBUS vs CLXT
CBUS vs CLXT
Side-by-side comparison of Cibus Inc. (CBUS) and Calyxt Inc. (CLXT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and CLXT operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS is the larger of the two at $98.5M, about 1.6x CLXT ($62.0M).
- CBUS has hit the wire 11 times in the past 4 weeks while CLXT has been quiet.
- CBUS has more recent analyst coverage (4 ratings vs 2 for CLXT).
- Company
- Cibus Inc.
- Calyxt Inc.
- Price
- $1.27-0.78%
- $31.50+428.97%
- Market cap
- $98.5M
- $62.0M
- 1M return
- -16.12%
- -
- 1Y return
- -23.19%
- -
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2017
- News (4w)
- 11
- 0
- Recent ratings
- 4
- 2
Calyxt Inc.
Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and various geographies outside the United States. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
Latest CBUS
- Cibus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Finn Mark Terrence
- SEC Form 4 filed by Director Moretti August J
- SEC Form 4 filed by Director Riggs Rory B
- Director Prante Gerhard was granted 64,748 shares, increasing direct ownership by 161% to 104,945 units (SEC Form 4)
- Director Lehmann Jean-Pierre Jules was granted 64,748 shares, increasing direct ownership by 9% to 763,904 units (SEC Form 4)
- SEC Form 4 filed by Director Box Kimberly Ann
- SEC Form 4 filed by Director Wichner Craig
- Director Urban Thomas was granted 64,748 shares (SEC Form 4)
- SEC Form EFFECT filed by Cibus Inc.
Latest CLXT
- Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
- SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)
- Calyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Riggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)
- Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Calyxt Inc.
- Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)
- Calyxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Calyxt Inc.